146 related articles for article (PubMed ID: 17975148)
1. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.
Gamelin L; Capitain O; Morel A; Dumont A; Traore S; Anne le B; Gilles S; Boisdron-Celle M; Gamelin E
Clin Cancer Res; 2007 Nov; 13(21):6359-68. PubMed ID: 17975148
[TBL] [Abstract][Full Text] [Related]
2. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia.
Sakurai M; Egashira N; Kawashiri T; Yano T; Ikesue H; Oishi R
Pain; 2009 Dec; 147(1-3):165-74. PubMed ID: 19782472
[TBL] [Abstract][Full Text] [Related]
4. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
5. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
Kweekel DM; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
[TBL] [Abstract][Full Text] [Related]
7. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
Grolleau F; Gamelin L; Boisdron-Celle M; Lapied B; Pelhate M; Gamelin E
J Neurophysiol; 2001 May; 85(5):2293-7. PubMed ID: 11353042
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin and axonal Na+ channel function in vivo.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.
Ali BH
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):272-9. PubMed ID: 20050845
[TBL] [Abstract][Full Text] [Related]
13. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat.
Cavaletti G; Petruccioli MG; Marmiroli P; Rigolio R; Galbiati S; Zoia C; Ferrarese C; Tagliabue E; Dolci C; Bayssas M; Griffon Etienne G; Tredici G
Anticancer Res; 2002; 22(6C):4199-204. PubMed ID: 12553056
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxic effect of oxaliplatin: Comparison with its oxalate-free analogue cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)] (LLC-1402) in mice.
Pereira AF; de Oliveira FFB; de Freitas Alves BW; de Menezes KLS; de Mesquita AKV; Lisboa MRP; de Sousa KKO; Vale ML
Toxicol Appl Pharmacol; 2018 Feb; 340():77-84. PubMed ID: 29307816
[TBL] [Abstract][Full Text] [Related]
15. Hepatic alanine-glyoxylate aminotransferase activity and oxalate metabolism in vitamin B6 deficient rats.
Nishijima S; Sugaya K; Morozumi M; Hatano T; Ogawa Y
J Urol; 2003 Feb; 169(2):683-6. PubMed ID: 12544342
[TBL] [Abstract][Full Text] [Related]
16. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis.
Holmes RP; Assimos DG
J Urol; 1998 Nov; 160(5):1617-24. PubMed ID: 9783918
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
18. A review on oxaliplatin-induced peripheral nerve damage.
Argyriou AA; Polychronopoulos P; Iconomou G; Chroni E; Kalofonos HP
Cancer Treat Rev; 2008 Jun; 34(4):368-77. PubMed ID: 18281158
[TBL] [Abstract][Full Text] [Related]
19. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
20. [Formation of oxalate in oxaliplatin injection diluted with infusion solutions].
Eto S; Yamamoto K; Shimazu K; Sugiura T; Baba K; Sato A; Goromaru T; Hagiwara Y; Hara K; Shinohara Y; Takahashi K
Gan To Kagaku Ryoho; 2014 Jan; 41(1):71-5. PubMed ID: 24423955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
